cd30.car-ebvst cells
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Baylor College of MedicineCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
52 Active assets in the Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PEGASPARGASE CStone Pharmaceuticals | Phase 4 | BBB |
DEXAMETHASONE Mingzhi Zhang | Phase 4 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Centre, Singapore | Phase 4 | BBB |
ETOPOSIDE Tarapeutics Science Inc. | Phase 4 | BB |
Tucidinostat Ruijin Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
cd30.car-ebvst cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →